Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants.

Kim S, Lalani S, Parekh VV, Wu L, Van Kaer L
Expert Rev Vaccines. 2008 7 (10): 1519-32

PMID: 19053208 · PMCID: PMC2680388 · DOI:10.1586/14760584.7.10.1519

Invariant natural killer T (iNKT) cells are a unique subset of T lymphocytes that recognize glycolipid antigens in the context of the antigen-presenting molecule CD1d. Upon glycolipid antigen stimulation, iNKT cells rapidly produce copious amounts of immunomodulatory cytokines, leading to potent activation of a variety of innate and adaptive immune cells. These immune-potentiating properties of iNKT cells hold great promise for the development of vaccine adjuvants. This review aims to summarize the immunomodulatory activities of iNKT cell ligands and to discuss prospects for developing iNKT cell-based vaccine adjuvants.

MeSH Terms (3)

Adjuvants, Immunologic Glycolipids Natural Killer T-Cells

Connections (2)

This publication is referenced by other Labnodes entities: